A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis
Rheumatol Ther. 2023;10(6):1519–1533 doi 10.1007/s40744-023-00594-6
This study by Harrold, et al. showed that RA patients initiating upadacitinib reported improvements in RAPID3, pain, stiffness, and fatigue as early as Week 1, with 37.5% achieving RAPID3 LDA at Week 12. TNFi-experienced patients had similar outcomes.
PROs were assessed over a 12-week period via a mobile health app. These real-world data suggest that upadacitinib leads to early and significant improvements in RA symptoms, with high patient-reported medication convenience.
Keywords:
